marketcaparena
Search

    MDT

    Medtronic plc

    Company overview

    Market capitalization
    $114.48B
    Employees
    95,000
    Latest publication
    2026-09-29
    About Medtronic plc

    Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring sys

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20272026-07-31 · USDQ3 20262026-01-23 · USDQ2 20262025-10-31 · USDQ1 20262025-07-31 · USDQ4 20252025-04-30 · USDQ3 20252025-01-31 · USDQ2 20252024-10-31 · USDQ1 20252024-07-31 · USD
    Operating profit1,764,000,000USD———————
    Income tax provision289,000,000USD———————
    Income before income taxes1,769,000,000USD———————
    Other non operating expense (income), net-190,000,000USD———————
    Research and development expense771,000,000USD———————
    Basic weighted average shares outstanding1,279,800,000shares———————
    Cost of products sold, excluding amortization of intangible assets3,416,000,000USD———————
    Amortization of intangible assets412,000,000USD———————
    Net sales9,756,000,000USD———————
    Diluted weighted average shares outstanding1,285,100,000shares———————
    Restructuring charges, net72,000,000USD———————
    Basic earnings per share1.15USD/share———————
    Net income attributable to noncontrolling interests-9,000,000USD———————
    Interest expense, net186,000,000USD———————
    Net income1,479,000,000USD———————
    Net income attributable to Medtronic1,470,000,000USD———————
    Selling, general, and administrative expense3,198,000,000USD———————
    Other operating expense (income), net-123,000,000USD———————
    Diluted earnings per share1.14USD/share———————
    Total Revenue—9,017,000,000USD8,961,000,000USD8,578,000,000USD8,927,000,000USD8,292,000,000USD8,403,000,000USD7,915,000,000USD
    Cost Of Revenue—3,261,000,000USD3,556,000,000USD3,632,000,000USD3,147,000,000USD2,779,000,000USD2,946,000,000USD2,761,000,000USD
    Gross Profit—5,756,000,000USD5,405,000,000USD4,946,000,000USD5,780,000,000USD5,513,000,000USD5,457,000,000USD5,154,000,000USD
    Research Development—722,000,000USD754,000,000USD726,000,000USD684,000,000USD675,000,000USD697,000,000USD676,000,000USD
    Selling General Administrative—2,956,000,000USD2,965,000,000USD2,806,000,000USD2,720,000,000USD2,717,000,000USD2,757,000,000USD2,655,000,000USD
    Total Operating Expenses—4,292,000,000USD3,720,000,000USD3,501,000,000USD4,344,000,000USD3,867,000,000USD3,862,000,000USD3,876,000,000USD
    Operating Income—1,464,000,000USD1,685,000,000USD1,445,000,000USD1,436,000,000USD1,646,000,000USD1,595,000,000USD1,278,000,000USD
    Total Other Income Expense Net—-60,000,000USD-89,000,000USD-143,000,000USD-175,000,000USD-106,000,000USD-36,000,000USD-10,000,000USD
    Interest Expense—181,000,000USD181,000,000USD176,000,000USD174,000,000USD179,000,000USD209,000,000USD167,000,000USD
    Net Interest Income—85,000,000USD-181,000,000USD-176,000,000USD-174,000,000USD-179,000,000USD-209,000,000USD-167,000,000USD
    Income Before Tax—1,404,000,000USD1,596,000,000USD1,302,000,000USD1,261,000,000USD1,540,000,000USD1,559,000,000USD1,268,000,000USD
    Income Tax Expense—254,000,000USD215,000,000USD255,000,000USD199,000,000USD237,000,000USD281,000,000USD220,000,000USD
    Net Income—1,150,000,000USD1,374,000,000USD1,040,000,000USD1,057,000,000USD1,294,000,000USD1,270,000,000USD1,042,000,000USD
    Minority Interest—6,000,000USD-7,000,000USD-7,000,000USD-5,000,000USD-9,000,000USD-9,000,000USD-6,000,000USD
    Net Income Applicable To Common Shares—1,143,000,000USD1,374,000,000USD1,040,000,000USD1,056,000,000USD1,294,000,000USD1,270,000,000USD—
    Interest Income——105,000,000USD256,000,000USD375,000,000USD135,000,000USD72,000,000USD—
    Tax Provision——215,000,000USD255,000,000USD199,000,000USD237,000,000USD281,000,000USD220,000,000USD
    Net Income From Continuing Ops——1,381,000,000USD1,047,000,000USD1,061,000,000USD1,303,000,000USD1,278,000,000USD1,049,000,000USD
    Ebit——1,777,000,000USD1,477,000,000USD1,435,000,000USD1,719,000,000USD1,768,000,000USD1,435,000,000USD
    Ebitda——2,366,000,000USD2,225,000,000USD2,275,000,000USD2,403,000,000USD2,443,000,000USD2,097,000,000USD
    Depreciation And Amortization——589,000,000USD748,000,000USD840,000,000USD684,000,000USD675,000,000USD662,000,000USD
    Reconciled Depreciation——745,000,000USD748,000,000USD840,000,000USD684,000,000USD675,000,000USD662,000,000USD
    Unclassified Operating Expenses————940,000,000USD475,000,000USD408,000,000USD545,000,000USD
    SourceDisclosureVerifiedDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-04-24 · USDFY 20252025-04-30 · USDFY 20242024-04-30 · USDFY 20232023-04-30 · USDFY 20222022-04-30 · USDFY 20212021-04-30 · USDFY 20202020-04-30 · USDFY 20192019-04-30 · USD
    Total Revenue36,364,000,000USD33,537,000,000USD32,364,000,000USD31,227,000,000USD31,686,000,000USD30,117,000,000USD28,913,000,000USD30,557,000,000USD
    Cost Of Revenue12,721,000,000USD11,632,000,000USD11,216,000,000USD10,719,000,000USD10,145,000,000USD10,483,000,000USD9,424,000,000USD9,155,000,000USD
    Gross Profit23,643,000,000USD21,905,000,000USD21,148,000,000USD20,508,000,000USD21,541,000,000USD19,634,000,000USD19,489,000,000USD21,402,000,000USD
    Research Development2,873,000,000USD2,732,000,000USD2,735,000,000USD2,696,000,000USD2,746,000,000USD2,493,000,000USD2,331,000,000USD2,330,000,000USD
    Selling General Administrative11,784,000,000USD10,849,000,000USD10,736,000,000USD10,415,000,000USD10,292,000,000USD10,148,000,000USD9,875,000,000USD10,232,000,000USD
    Total Operating Expenses17,176,000,000USD15,950,000,000USD16,004,000,000USD15,023,000,000USD15,789,000,000USD15,150,000,000USD14,698,000,000USD15,134,000,000USD
    Operating Income6,467,000,000USD5,955,000,000USD5,144,000,000USD5,485,000,000USD5,752,000,000USD4,484,000,000USD4,791,000,000USD6,268,000,000USD
    Total Other Income Expense Net-331,000,000USD-327,000,000USD-307,000,000USD-121,000,000USD-235,000,000USD-589,000,000USD-736,000,000USD-1,071,000,000USD
    Interest Expense715,000,000USD729,000,000USD719,000,000USD636,000,000USD553,000,000USD925,000,000USD1,092,000,000USD1,444,000,000USD
    Net Interest Income383,000,000USD-729,000,000USD-719,000,000USD-636,000,000USD-553,000,000USD-925,000,000USD-1,092,000,000USD-1,444,000,000USD
    Income Before Tax6,136,000,000USD5,628,000,000USD4,837,000,000USD5,364,000,000USD5,517,000,000USD3,895,000,000USD4,055,000,000USD5,197,000,000USD
    Income Tax Expense1,299,000,000USD936,000,000USD1,133,000,000USD1,580,000,000USD456,000,000USD265,000,000USD-751,000,000USD547,000,000USD
    Net Income4,837,000,000USD4,662,000,000USD3,676,000,000USD3,758,000,000USD5,039,000,000USD3,606,000,000USD4,789,000,000USD4,631,000,000USD
    Minority Interest37,000,000USD-29,000,000USD-28,000,000USD-26,000,000USD-22,000,000USD174,000,000USD17,000,000USD121,000,000USD
    Net Income Applicable To Common Shares4,801,000,000USD4,662,000,000USD3,676,000,000USD3,758,000,000USD5,039,000,000USD3,606,000,000USD4,789,000,000USD4,631,000,000USD
    Unclassified Operating Expenses—2,369,000,000USD2,533,000,000USD1,912,000,000USD2,751,000,000USD2,509,000,000USD2,492,000,000USD2,572,000,000USD
    Interest Income—612,000,000USD721,000,000USD164,000,000USD541,000,000USD617,000,000USD379,000,000USD676,000,000USD
    Tax Provision—936,000,000USD1,133,000,000USD1,580,000,000USD456,000,000USD265,000,000USD-751,000,000USD547,000,000USD
    Net Income From Continuing Ops—4,691,000,000USD3,705,000,000USD3,784,000,000USD5,062,000,000USD3,630,000,000USD4,806,000,000USD4,650,000,000USD
    Ebit—6,357,000,000USD5,556,000,000USD6,000,000,000USD6,070,000,000USD4,820,000,000USD5,147,000,000USD6,641,000,000USD
    Ebitda—9,218,000,000USD8,203,000,000USD8,697,000,000USD8,777,000,000USD7,522,000,000USD7,810,000,000USD9,300,000,000USD
    Depreciation And Amortization—2,861,000,000USD2,647,000,000USD2,697,000,000USD2,707,000,000USD2,702,000,000USD2,663,000,000USD2,659,000,000USD
    Reconciled Depreciation—2,861,000,000USD2,647,000,000USD2,697,000,000USD2,707,000,000USD2,702,000,000USD2,663,000,000USD2,659,000,000USD
    Non Operating Income Net Other———515,000,000USD318,000,000USD336,000,000USD356,000,000USD373,000,000USD
    Discontinued Operations———————0USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20272026-07-31 · USDQ4 20262026-04-24 · USDQ3 20262026-01-23 · USDQ2 20262025-10-31 · USDQ1 20262025-07-31 · USDQ4 20252025-04-30 · USDQ3 20252025-01-31 · USDQ2 20252024-10-31 · USD
    Accumulated other comprehensive loss-3,759,000,000USD———————
    Goodwill43,187,000,000USD42,587,000,000USD41,892,000,000USD—————
    Other accrued expenses3,606,000,000USD———————
    Deferred tax liabilities349,000,000USD———————
    Total equity50,850,000,000USD———————
    Current debt obligations2,536,000,000USD———————
    Retained earnings33,187,000,000USD———————
    Accrued income taxes1,056,000,000USD———————
    Other assets4,315,000,000USD———————
    Total assets93,306,000,000USD———————
    Cash and cash equivalents1,691,000,000USD———————
    Total current assets24,390,000,000USD———————
    Investments7,128,000,000USD———————
    Additional paid in capital20,805,000,000USD———————
    Total liabilities42,456,000,000USD———————
    Accounts receivable, less allowances for credit losses of $203 and $190, respectively6,357,000,000USD———————
    Accounts payable2,695,000,000USD———————
    Long term debt25,617,000,000USD———————
    Total liabilities and equity93,306,000,000USD———————
    Accrued compensation1,906,000,000USD———————
    Total shareholders’ equity50,232,000,000USD———————
    Other liabilities2,001,000,000USD———————
    Noncontrolling interests618,000,000USD———————
    Accrued compensation and retirement benefits1,167,000,000USD———————
    Other current assets2,999,000,000USD———————
    Total current liabilities11,799,000,000USD———————
    Inventories6,215,000,000USD———————
    Property, plant, and equipment, net7,473,000,000USD———————
    Other intangible assets, net10,238,000,000USD———————
    Tax assets3,703,000,000USD———————
    Total Assets—93,028,000,000USD91,485,000,000USD91,346,000,000USD90,972,000,000USD91,680,000,000USD89,973,000,000USD90,042,000,000USD
    Cash And Equivalents—1,949,000,000USD1,147,000,000USD1,282,000,000USD1,273,000,000USD2,218,000,000USD1,240,000,000USD1,394,000,000USD
    Cash And Short Term Investments—9,220,000,000USD8,383,000,000USD8,327,000,000USD8,121,000,000USD8,965,000,000USD7,922,000,000USD7,989,000,000USD
    Short Term Investments—7,271,000,000USD7,236,000,000USD7,045,000,000USD6,848,000,000USD6,747,000,000USD6,682,000,000USD6,595,000,000USD
    Total Current Assets—24,787,000,000USD24,071,000,000USD23,996,000,000USD23,223,000,000USD23,814,000,000USD22,513,000,000USD22,438,000,000USD
    Other Current Assets—2,972,000,000USD3,020,000,000USD3,124,000,000USD9,212,000,000USD2,858,000,000USD2,866,000,000USD2,710,000,000USD
    Other Non Current Assets—4,147,000,000USD4,041,000,000USD—————
    Total Liabilities—42,956,000,000USD42,289,000,000USD—————
    Total Current Liabilities—11,658,000,000USD9,495,000,000USD9,935,000,000USD11,530,000,000USD12,879,000,000USD11,840,000,000USD12,195,000,000USD
    Other Current Liabilities—3,634,000,000USD3,504,000,000USD—————
    Other Non Current Liabilities—2,055,000,000USD1,770,000,000USD—————
    Total Stockholder Equity—49,463,000,000USD48,985,000,000USD48,652,000,000USD47,893,000,000USD48,024,000,000USD49,387,000,000USD48,494,000,000USD
    Total Equity Including Noncontrolling Interest—50,072,000,000USD49,196,000,000USD—————
    Long Term Debt—26,173,000,000USD27,880,000,000USD27,625,000,000USD26,128,000,000USD25,590,000,000USD23,935,000,000USD24,557,000,000USD
    Net Receivables—6,643,000,000USD6,359,000,000USD6,389,000,000USD6,263,000,000USD6,515,000,000USD6,115,000,000USD6,260,000,000USD
    Inventory—5,951,000,000USD6,309,000,000USD6,156,000,000USD-373,000,000USD5,476,000,000USD5,610,000,000USD5,479,000,000USD
    Property Plant Equipment Net—8,614,000,000USD7,179,000,000USD7,164,000,000USD-504,000,000USD6,837,000,000USD6,593,000,000USD6,438,000,000USD
    Intangible Assets—10,146,000,000USD10,335,000,000USD10,770,000,000USD11,223,000,000USD11,667,000,000USD12,185,000,000USD12,424,000,000USD
    Accounts Payable—2,644,000,000USD2,569,000,000USD2,581,000,000USD2,555,000,000USD2,449,000,000USD2,286,000,000USD2,376,000,000USD
    Short Term Debt—1,788,000,000USD191,000,000USD1,420,000,000USD2,430,000,000USD2,874,000,000USD2,622,000,000USD3,719,000,000USD
    Common Stock—0USD0USD128,100USD-28,000,000USD128,190USD0USD128,250USD
    Retained Earnings—32,638,000,000USD32,303,000,000USD32,070,000,000USD31,606,000,000USD31,476,000,000USD31,317,000,000USD30,919,000,000USD
    Accumulated Other Comprehensive Income—-4,101,000,000USD-4,330,000,000USD-4,275,000,000USD-4,604,000,000USD-4,284,000,000USD-2,839,000,000USD-3,250,000,000USD
    Total Liab———42,489,000,000USD42,839,000,000USD43,424,000,000USD40,358,000,000USD41,326,000,000USD
    Other Current Liab———5,934,000,000USD6,143,000,000USD6,198,000,000USD5,807,000,000USD5,153,000,000USD
    Capital Stock———0USD0USD0USD0USD0USD
    Good Will———41,811,000,000USD42,007,000,000USD41,737,000,000USD40,819,000,000USD41,161,000,000USD
    Other Assets———6,754,000,000USD6,663,000,000USD1,000,000USD-1,000,000USD6,319,000,000USD
    Cash———1,282,000,000USD1,273,000,000USD2,218,000,000USD1,240,000,000USD1,394,000,000USD
    Net Debt———27,818,000,000USD27,336,000,000USD26,298,000,000USD25,367,000,000USD26,932,000,000USD
    Short Long Term Debt———1,420,000,000USD2,430,000,000USD2,868,000,000USD2,622,000,000USD3,719,000,000USD
    Short Long Term Debt Total———29,100,000,000USD28,609,000,000USD28,516,000,000USD26,607,000,000USD28,326,000,000USD
    Common Stock Shares Outstanding———1,287,500,000shares1,287,100,000shares1,287,700,000shares1,286,200,000shares1,286,900,000shares
    Non Current Assets Total———67,350,000,000USD67,749,000,000USD67,865,000,000USD67,461,000,000USD67,604,000,000USD
    Non Current Liabilities Total———32,554,000,000USD31,309,000,000USD30,545,000,000USD28,518,000,000USD29,131,000,000USD
    Non Current Liabilities Other———1,765,000,000USD1,813,000,000USD1,768,000,000USD1,533,000,000USD1,535,000,000USD
    Non Currrent Assets Other———7,605,000,000USD15,023,000,000USD7,624,000,000USD7,864,000,000USD7,581,000,000USD
    Net Working Capital———14,061,000,000USD11,693,000,000USD10,935,000,000USD10,673,000,000USD10,243,000,000USD
    Unclassified Non Current Assets———-6,754,000,000USD-7,167,000,000USD——-6,319,000,000USD
    Unclassified Current Liabilities———-1,420,000,000USD-2,028,000,000USD-1,510,000,000USD-1,497,000,000USD-2,772,000,000USD
    Unclassified Non Current Liabilities———3,164,000,000USD3,368,000,000USD3,187,000,000USD3,050,000,000USD3,039,000,000USD
    Unclassified Equity———20,856,871,900USD20,919,000,000USD20,831,871,810USD20,909,000,000USD20,824,871,750USD
    Unclassified Current Assets————-373,000,000USD———
    Property Plant Equipment Gross—————15,636,000,000USD——
    SourceDisclosureVerifiedDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-04-24 · USDFY 20252025-04-30 · USDFY 20242024-04-30 · USDFY 20232023-04-30 · USDFY 20222022-04-30 · USDFY 20212021-04-30 · USDFY 20202020-04-30 · USDFY 20192019-04-30 · USD
    Total Assets93,028,000,000USD91,680,000,000USD89,981,000,000USD90,948,000,000USD90,981,000,000USD93,083,000,000USD90,689,000,000USD89,694,000,000USD
    Cash And Equivalents1,949,000,000USD2,218,000,000USD1,284,000,000USD1,543,000,000USD3,714,000,000USD3,593,000,000USD4,140,000,000USD4,393,000,000USD
    Cash And Short Term Investments9,220,000,000USD8,965,000,000USD8,005,000,000USD7,959,000,000USD10,573,000,000USD10,817,000,000USD10,948,000,000USD9,848,000,000USD
    Short Term Investments7,271,000,000USD6,747,000,000USD6,721,000,000USD6,416,000,000USD6,859,000,000USD7,224,000,000USD6,808,000,000USD5,455,000,000USD
    Total Current Assets24,787,000,000USD23,814,000,000USD21,935,000,000USD21,675,000,000USD23,059,000,000USD22,548,000,000USD22,031,000,000USD21,967,000,000USD
    Other Current Assets2,972,000,000USD2,858,000,000USD2,585,000,000USD2,425,000,000USD2,319,000,000USD1,956,000,000USD2,209,000,000USD2,144,000,000USD
    Other Non Current Assets4,147,000,000USD———————
    Total Liabilities42,956,000,000USD———————
    Total Current Liabilities11,658,000,000USD12,879,000,000USD10,789,000,000USD9,051,000,000USD12,394,000,000USD8,509,000,000USD10,366,000,000USD8,472,000,000USD
    Other Current Liabilities3,634,000,000USD———————
    Other Non Current Liabilities2,055,000,000USD———————
    Total Stockholder Equity49,463,000,000USD48,024,000,000USD50,214,000,000USD51,483,000,000USD52,551,000,000USD51,428,000,000USD50,737,000,000USD50,091,000,000USD
    Total Equity Including Noncontrolling Interest50,072,000,000USD———————
    Long Term Debt26,173,000,000USD25,590,000,000USD23,877,000,000USD24,344,000,000USD20,372,000,000USD26,378,000,000USD21,976,000,000USD24,476,000,000USD
    Net Receivables6,643,000,000USD6,515,000,000USD6,128,000,000USD5,998,000,000USD5,551,000,000USD5,462,000,000USD4,645,000,000USD6,222,000,000USD
    Inventory5,951,000,000USD5,476,000,000USD5,217,000,000USD5,293,000,000USD4,616,000,000USD4,313,000,000USD4,229,000,000USD3,753,000,000USD
    Property Plant Equipment Net8,614,000,000USD6,837,000,000USD6,131,000,000USD5,569,000,000USD5,413,000,000USD5,221,000,000USD4,828,000,000USD4,675,000,000USD
    Goodwill42,587,000,000USD———————
    Intangible Assets10,146,000,000USD11,667,000,000USD13,225,000,000USD14,844,000,000USD15,594,000,000USD17,740,000,000USD19,063,000,000USD20,560,000,000USD
    Accounts Payable2,644,000,000USD2,449,000,000USD2,410,000,000USD2,662,000,000USD2,276,000,000USD2,106,000,000USD1,996,000,000USD1,953,000,000USD
    Short Term Debt1,788,000,000USD2,874,000,000USD1,092,000,000USD20,000,000USD3,742,000,000USD11,000,000USD2,776,000,000USD838,000,000USD
    Common Stock0USD128,190USD131,130USD133,100USD133,070USD134,540USD134,110USD134,070USD
    Retained Earnings32,638,000,000USD31,476,000,000USD30,403,000,000USD30,392,000,000USD30,250,000,000USD28,594,000,000USD28,132,000,000USD26,270,000,000USD
    Accumulated Other Comprehensive Income-4,101,000,000USD-4,284,000,000USD-3,318,000,000USD-3,499,000,000USD-2,265,000,000USD-3,485,000,000USD-3,560,000,000USD-2,711,000,000USD
    Total Liab—43,424,000,000USD39,561,000,000USD39,283,000,000USD38,259,000,000USD41,481,000,000USD39,817,000,000USD39,482,000,000USD
    Other Current Liab—7,556,000,000USD5,957,000,000USD5,529,000,000USD5,672,000,000USD5,957,000,000USD5,092,000,000USD5,114,000,000USD
    Capital Stock—0USD0USD0USD0USD0USD0USD0USD
    Good Will—41,737,000,000USD40,986,000,000USD41,425,000,000USD40,502,000,000USD41,961,000,000USD39,841,000,000USD39,959,000,000USD
    Other Assets—1,000,000USD5,410,000,000USD-1,000,000USD2,000,000USD1,000,000USD3,486,000,000USD2,108,000,000USD
    Cash—2,218,000,000USD1,284,000,000USD1,543,000,000USD3,714,000,000USD3,593,000,000USD4,140,000,000USD4,393,000,000USD
    Net Debt—26,298,000,000USD23,740,000,000USD22,821,000,000USD20,400,000,000USD22,796,000,000USD20,657,000,000USD20,922,000,000USD
    Short Long Term Debt—2,868,000,000USD1,086,000,000USD20,000,000USD3,742,000,000USD11,000,000USD2,771,000,000USD832,000,000USD
    Short Long Term Debt Total—28,516,000,000USD25,024,000,000USD24,364,000,000USD24,114,000,000USD26,389,000,000USD24,797,000,000USD25,315,000,000USD
    Property Plant Equipment Gross—15,636,000,000USD14,053,000,000USD14,062,000,000USD13,365,000,000USD5,221,000,000USD5,755,000,000USD4,675,000,000USD
    Common Stock Shares Outstanding—1,289,900,000shares1,330,200,000shares1,332,800,000shares1,351,400,000shares1,354,000,000shares1,351,100,000shares1,357,500,000shares
    Non Current Assets Total—67,865,000,000USD68,046,000,000USD69,274,000,000USD67,920,000,000USD70,534,000,000USD68,658,000,000USD67,727,000,000USD
    Non Current Liabilities Total—30,545,000,000USD28,772,000,000USD30,232,000,000USD25,865,000,000USD32,972,000,000USD29,451,000,000USD31,010,000,000USD
    Non Current Liabilities Other—1,768,000,000USD1,365,000,000USD1,727,000,000USD1,409,000,000USD1,758,000,000USD6,256,000,000USD757,000,000USD
    Non Currrent Assets Other—7,624,000,000USD7,704,000,000USD7,436,000,000USD6,411,000,000USD5,612,000,000USD4,926,000,000USD2,533,000,000USD
    Net Working Capital—10,935,000,000USD11,146,000,000USD12,624,000,000USD10,665,000,000USD14,039,000,000USD11,665,000,000USD13,495,000,000USD
    Unclassified Current Liabilities—-2,868,000,000USD244,000,000USD506,000,000USD-3,343,000,000USD148,000,000USD-2,269,000,000USD-580,000,000USD
    Unclassified Non Current Liabilities—3,187,000,000USD3,530,000,000USD-3,318,000,000USD-2,293,000,000USD-1,957,000,000USD-6,611,000,000USD-2,025,000,000USD
    Unclassified Equity—20,831,871,810USD23,128,868,870USD24,589,866,900USD24,565,866,930USD26,318,865,460USD26,164,865,890USD26,531,865,930USD
    Current Deferred Revenue——-1,330,000,000USD314,000,000USD305,000,000USD276,000,000USD—315,000,000USD
    Unclassified Non Current Assets——-5,410,000,000USD———-3,486,000,000USD-2,524,000,000USD
    Deferred Long Term Liab———708,000,000USD884,000,000USD1,028,000,000USD1,174,000,000USD1,278,000,000USD
    Other Liab———6,771,000,000USD5,493,000,000USD5,765,000,000USD6,656,000,000USD6,524,000,000USD
    Net Tangible Assets———51,483,000,000USD-3,546,000,000USD-8,273,000,000USD50,737,000,000USD-10,428,000,000USD
    Long Term Investments———————416,000,000USD
    Additional Paid In Capital———————0USD
    Treasury Stock———————0USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20272026-07-31 · USDQ3 20262026-01-23 · USD
    Net cash used in investing activities-1,619,000,000USD—
    Issuance of ordinary shares20,000,000USD—
    Sales and maturities of investments2,209,000,000USD—
    Accounts receivable, net-224,000,000USD—
    Dividends to shareholders-921,000,000USD—
    Stock based compensation125,000,000USD—
    Net cash used in financing activities-343,000,000USD—
    Accounts payable and accrued liabilities-531,000,000USD—
    Income taxes199,000,000USD—
    Repurchase of ordinary shares-267,000,000USD—
    Purchases of investments-2,190,000,000USD—
    Provision for credit losses25,000,000USD—
    Net change in cash and cash equivalents-258,000,000USD—
    Other operating assets and liabilities-118,000,000USD—
    Other, net-29,000,000USD—
    Net income1,479,000,000USD—
    Depreciation and amortization729,000,000USD—
    Additions to property, plant, and equipment-503,000,000USD—
    Cash and cash equivalents at beginning of period1,949,000,000USD—
    Acquisitions, net of cash acquired-1,162,000,000USD—
    Effect of exchange rate changes on cash and cash equivalents-89,000,000USD—
    Deferred income taxes127,000,000USD—
    Other financing activities, net13,000,000USD—
    Inventories-240,000,000USD—
    Other investing activities, net-26,000,000USD—
    Interest83,000,000USD—
    Change in current debt obligations, net812,000,000USD—
    Cash and cash equivalents at end of period1,691,000,000USD—
    Net cash provided by operating activities1,793,000,000USD—
    Depreciation—2,242,000,000USD
    Stock Based Compensation—362,000,000USD
    Deferred Income Tax—59,000,000USD
    Other Non Cash Items—-280,000,000USD
    Change To Inventory—-803,000,000USD
    Change To Liabilities—-77,000,000USD
    Change In Working Capital—-880,000,000USD
    Operating Cash Flow—4,757,000,000USD
    Capital Expenditures—-1,416,000,000USD
    Net Investments—5,310,000,000USD
    Other Investing Activities—10,000,000USD
    Unclassified Investing Cash Flow—-5,921,000,000USD
    Investing Cash Flow—-2,017,000,000USD
    Net Debt Issuance—-1,010,000,000USD
    Net Common Stock Issuance—-600,000,000USD
    Common Dividends Paid—-2,731,000,000USD
    Other Financing Activities—60,000,000USD
    Unclassified Financing Cash Flow—418,000,000USD
    Financing Cash Flow—-3,863,000,000USD
    Effect Of Forex Changes On Cash—52,000,000USD
    Change In Cash—-1,072,000,000USD
    End Cash Flow—1,147,000,000USD
    SourceDisclosureVerifiedDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20272026-07-31 · USDQ4 20262026-04-30 · USDQ3 20262026-01-31 · USDQ2 20262025-10-31 · USDQ1 20262025-07-31 · USDQ4 20252025-04-30 · USDQ3 20252025-01-31 · USDQ2 20252024-10-31 · USD
    Depreciation729,000,000USD625,000,000USD840,000,000USD745,000,000USD748,000,000USD840,000,000USD684,000,000USD675,000,000USD
    Stock Based Compensation125,000,000USD95,000,000USD94,000,000USD182,000,000USD86,000,000USD89,000,000USD98,000,000USD159,000,000USD
    Deferred Income Tax127,000,000USD———————
    Other Non Cash Items29,000,000USD144,000,000USD66,000,000USD53,000,000USD187,000,000USD327,000,000USD172,000,000USD-2,028,000,000USD
    Change To Inventory-240,000,000USD399,000,000USD-131,000,000USD-299,000,000USD-373,000,000USD186,000,000USD-200,000,000USD-61,000,000USD
    Change To Liabilities-531,000,000USD———————
    Change In Working Capital-771,000,000USD444,000,000USD702,000,000USD-1,422,000,000USD-1,147,000,000USD450,000,000USD462,000,000USD905,000,000USD
    Operating Cash Flow1,793,000,000USD———————
    Capital Expenditures-503,000,000USD-488,000,000USD-444,000,000USD-468,000,000USD-504,000,000USD-459,000,000USD-476,000,000USD-404,000,000USD
    Net Investments2,219,000,000USD———————
    Other Investing Activities-1,188,000,000USD———————
    Unclassified Investing Cash Flow-2,147,000,000USD-406,000,000USD—329,000,000USD629,000,000USD597,000,000USD588,000,000USD386,000,000USD
    Investing Cash Flow-1,619,000,000USD———————
    Net Debt Issuance812,000,000USD———————
    Net Common Stock Issuance-267,000,000USD———————
    Common Dividends Paid-921,000,000USD———————
    Other Financing Activities13,000,000USD———————
    Unclassified Financing Cash Flow20,000,000USD96,000,000USD164,000,000USD160,000,000USD95,000,000USD108,000,000USD168,000,000USD143,000,000USD
    Financing Cash Flow-343,000,000USD———————
    Effect Of Forex Changes On Cash-89,000,000USD———————
    Change In Cash-258,000,000USD802,000,000USD-135,000,000USD9,000,000USD-945,000,000USD978,000,000USD-154,000,000USD83,000,000USD
    End Cash Flow1,691,000,000USD———————
    Net Income—1,273,000,000USD1,143,000,000USD1,374,000,000USD1,047,000,000USD1,057,000,000USD1,294,000,000USD1,278,000,000USD
    Change To Account Receivables—-287,000,000USD13,000,000USD-214,000,000USD288,000,000USD-249,000,000USD-3,000,000USD-291,000,000USD
    Total Cash From Operating Activities—2,573,000,000USD2,744,000,000USD925,000,000USD1,088,000,000USD2,528,000,000USD2,572,000,000USD958,000,000USD
    Free Cash Flow—2,085,000,000USD2,300,000,000USD457,000,000USD584,000,000USD2,069,000,000USD2,096,000,000USD554,000,000USD
    Investments—-30,000,000USD-347,000,000USD-482,000,000USD-719,000,000USD-490,000,000USD-843,000,000USD-345,000,000USD
    Total Cashflows From Investing Activities—-917,000,000USD-816,000,000USD-482,000,000USD-719,000,000USD-490,000,000USD-843,000,000USD-345,000,000USD
    Net Borrowings—-164,000,000USD-1,229,000,000USD732,000,000USD-513,000,000USD0USD-1,003,000,000USD557,000,000USD
    Total Cash From Financing Activities—-888,000,000USD-2,087,000,000USD-395,000,000USD-1,381,000,000USD-1,343,000,000USD-1,753,000,000USD-534,000,000USD
    Dividends Paid—-908,000,000USD-911,000,000USD-910,000,000USD-910,000,000USD-897,000,000USD-897,000,000USD-897,000,000USD
    Sale Purchase Of Stock—-435,000,000USD-105,000,000USD-372,000,000USD-123,000,000USD-274,000,000USD-181,000,000USD-288,000,000USD
    Issuance Of Capital Stock—635,000,000USD164,000,000USD160,000,000USD95,000,000USD108,000,000USD168,000,000USD143,000,000USD
    Begin Period Cash Flow—1,147,000,000USD1,282,000,000USD1,273,000,000USD2,218,000,000USD1,240,000,000USD1,394,000,000USD1,311,000,000USD
    End Period Cash Flow—1,949,000,000USD1,147,000,000USD1,282,000,000USD1,273,000,000USD2,218,000,000USD1,240,000,000USD1,394,000,000USD
    Other Cashflows From Investing Activities—7,000,000USD-25,000,000USD139,000,000USD-125,000,000USD-138,000,000USD-112,000,000USD18,000,000USD
    Other Cashflows From Financing Activities—523,000,000USD-6,000,000USD-5,000,000USD70,000,000USD-280,000,000USD160,000,000USD-49,000,000USD
    Unclassified Operating Cash Flow——-101,000,000USD—167,000,000USD-235,000,000USD-138,000,000USD-31,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-04-24 · USDFY 20252025-04-30 · USDFY 20242024-04-30 · USDFY 20232023-04-30 · USDFY 20222022-04-30 · USDFY 20212021-04-30 · USDFY 20202020-04-30 · USDFY 20192019-04-30 · USD
    Depreciation2,958,000,000USD2,861,000,000USD2,647,000,000USD2,697,000,000USD2,707,000,000USD2,702,000,000USD2,663,000,000USD2,659,000,000USD
    Stock Based Compensation457,000,000USD429,000,000USD393,000,000USD355,000,000USD359,000,000USD344,000,000USD297,000,000USD290,000,000USD
    Deferred Income Tax31,000,000USD———————
    Other Non Cash Items-314,000,000USD433,000,000USD1,063,000,000USD396,000,000USD711,000,000USD687,000,000USD722,000,000USD792,000,000USD
    Change To Inventory-404,000,000USD-292,000,000USD-139,000,000USD-939,000,000USD-560,000,000USD78,000,000USD-577,000,000USD-274,000,000USD
    Change To Liabilities46,000,000USD——696,000,000USD213,000,000USD531,000,000USD-44,000,000USD399,000,000USD
    Change In Working Capital-358,000,000USD-1,054,000,000USD-484,000,000USD-967,000,000USD-889,000,000USD-701,000,000USD61,000,000USD-1,080,000,000USD
    Operating Cash Flow7,330,000,000USD———————
    Capital Expenditures-1,904,000,000USD-1,859,000,000USD-1,587,000,000USD-1,459,000,000USD-1,368,000,000USD-1,355,000,000USD-1,213,000,000USD-1,134,000,000USD
    Net Investments7,380,000,000USD———————
    Other Investing Activities-402,000,000USD———————
    Unclassified Investing Cash Flow-8,008,000,000USD2,108,000,000USD1,848,000,000USD3,322,000,000USD-91,000,000USD-994,000,000USD—-2,208,000,000USD
    Investing Cash Flow-2,934,000,000USD———————
    Net Debt Issuance-1,174,000,000USD———————
    Net Common Stock Issuance-1,035,000,000USD———————
    Common Dividends Paid-3,639,000,000USD———————
    Other Financing Activities44,000,000USD———————
    Unclassified Financing Cash Flow1,053,000,000USD508,000,000USD284,000,000USD-7,385,000,000USD429,000,000USD-9,487,000,000USD-4,889,000,000USD838,000,000USD
    Financing Cash Flow-4,751,000,000USD———————
    Effect Of Forex Changes On Cash85,000,000USD———————
    Change In Cash-269,000,000USD934,000,000USD-259,000,000USD-2,171,000,000USD121,000,000USD-547,000,000USD-253,000,000USD724,000,000USD
    End Cash Flow1,949,000,000USD———————
    Net Income—4,691,000,000USD3,676,000,000USD3,784,000,000USD5,062,000,000USD3,630,000,000USD4,806,000,000USD4,650,000,000USD
    Change To Account Receivables—-433,000,000USD-391,000,000USD-576,000,000USD-477,000,000USD-761,000,000USD1,291,000,000USD-581,000,000USD
    Total Cash From Operating Activities—7,044,000,000USD6,787,000,000USD6,039,000,000USD7,346,000,000USD6,240,000,000USD7,234,000,000USD7,007,000,000USD
    Free Cash Flow—5,185,000,000USD5,200,000,000USD4,580,000,000USD5,978,000,000USD4,885,000,000USD6,021,000,000USD5,873,000,000USD
    Investments—-1,937,000,000USD-2,366,000,000USD-3,493,000,000USD-190,000,000USD-463,000,000USD-1,465,000,000USD2,532,000,000USD
    Total Cashflows From Investing Activities—-1,937,000,000USD-2,366,000,000USD-3,493,000,000USD-1,659,000,000USD-2,866,000,000USD-3,203,000,000USD-774,000,000USD
    Net Borrowings—2,139,000,000USD1,073,000,000USD-598,000,000USD-1,000,000USD-570,000,000USD-559,000,000USD-713,000,000USD
    Total Cash From Financing Activities—-4,361,000,000USD-4,450,000,000USD-4,960,000,000USD-5,336,000,000USD-4,136,000,000USD-4,198,000,000USD-5,431,000,000USD
    Dividends Paid—-3,589,000,000USD-3,666,000,000USD-3,616,000,000USD-3,383,000,000USD-3,121,000,000USD-2,894,000,000USD-2,693,000,000USD
    Sale Purchase Of Stock—-3,235,000,000USD-2,138,000,000USD-645,000,000USD-2,544,000,000USD-652,000,000USD-1,326,000,000USD-2,877,000,000USD
    Issuance Of Capital Stock—508,000,000USD284,000,000USD308,000,000USD429,000,000USD474,000,000USD662,000,000USD992,000,000USD
    Begin Period Cash Flow—1,284,000,000USD1,543,000,000USD3,714,000,000USD3,593,000,000USD4,140,000,000USD4,393,000,000USD3,669,000,000USD
    End Period Cash Flow—2,218,000,000USD1,284,000,000USD1,543,000,000USD3,714,000,000USD3,593,000,000USD4,140,000,000USD4,393,000,000USD
    Other Cashflows From Investing Activities—-249,000,000USD-261,000,000USD-1,863,000,000USD-10,000,000USD-54,000,000USD-525,000,000USD36,000,000USD
    Other Cashflows From Financing Activities—-184,000,000USD-3,000,000USD7,284,000,000USD163,000,000USD9,694,000,000USD5,470,000,000USD14,000,000USD
    Unclassified Operating Cash Flow—-316,000,000USD-508,000,000USD-226,000,000USD-604,000,000USD-422,000,000USD-1,315,000,000USD-304,000,000USD
    Cash And Cash Equivalents Changes———-2,414,000,000USD351,000,000USD-762,000,000USD-167,000,000USD802,000,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    FY 2026Yearly · 2026-04-24GeographyIE143,000,000USDDisclosure
    FY 2026Yearly · 2026-04-24GeographyInternational18,261,000,000USDDisclosure
    FY 2026Yearly · 2026-04-24GeographyUnited States18,103,000,000USDDisclosure
    FY 2026Yearly · 2026-04-24SegmentCardiovascular13,976,000,000USDDisclosure
    FY 2026Yearly · 2026-04-24SegmentDiabetes Group3,112,000,000USDDisclosure
    FY 2026Yearly · 2026-04-24SegmentMedical Surgical8,815,000,000USDDisclosure
    FY 2026Yearly · 2026-04-24SegmentNeuroscience Group10,287,000,000USDDisclosure
    FY 2026Yearly · 2026-04-24SegmentOther Operating Segment Misc174,000,000USDDisclosure
    Q3 2026Quarterly · 2026-01-23GeographyIE36,000,000USDDisclosure
    Q3 2026Quarterly · 2026-01-23GeographyInternational4,524,000,000USDDisclosure
    Q3 2026Quarterly · 2026-01-23GeographyUnited States4,493,000,000USDDisclosure
    Q3 2026Quarterly · 2026-01-23SegmentAll Other Segments32,000,000USDDisclosure
    Q3 2026Quarterly · 2026-01-23SegmentCardiovascular3,457,000,000USDDisclosure
    Q3 2026Quarterly · 2026-01-23SegmentDiabetes Group796,000,000USDDisclosure
    Q3 2026Quarterly · 2026-01-23SegmentMedical Surgical2,173,000,000USDDisclosure
    Q3 2026Quarterly · 2026-01-23SegmentNeuroscience Group2,558,000,000USDDisclosure
    Q2 2026Quarterly · 2025-10-31GeographyIE35,000,000USDDisclosure
    Q2 2026Quarterly · 2025-10-31GeographyInternational4,445,000,000USDDisclosure
    Q2 2026Quarterly · 2025-10-31GeographyUnited States4,516,000,000USDDisclosure
    Q2 2026Quarterly · 2025-10-31SegmentAll Other Segments35,000,000USDDisclosure
    Q2 2026Quarterly · 2025-10-31SegmentCardiovascular3,436,000,000USDDisclosure
    Q2 2026Quarterly · 2025-10-31SegmentDiabetes Group757,000,000USDDisclosure
    Q2 2026Quarterly · 2025-10-31SegmentMedical Surgical2,171,000,000USDDisclosure
    Q2 2026Quarterly · 2025-10-31SegmentNeuroscience Group2,562,000,000USDDisclosure
    Q1 2026Quarterly · 2025-07-31GeographyIE33,000,000USDDisclosure
    Q1 2026Quarterly · 2025-07-31GeographyInternational4,354,000,000USDDisclosure
    Q1 2026Quarterly · 2025-07-31GeographyUnited States4,224,000,000USDDisclosure
    Q1 2026Quarterly · 2025-07-31SegmentAll Other Segments33,000,000USDDisclosure
    Q1 2026Quarterly · 2025-07-31SegmentCardiovascular3,285,000,000USDDisclosure
    Q1 2026Quarterly · 2025-07-31SegmentDiabetes Group721,000,000USDDisclosure
    Q1 2026Quarterly · 2025-07-31SegmentMedical Surgical2,083,000,000USDDisclosure
    Q1 2026Quarterly · 2025-07-31SegmentNeuroscience Group2,416,000,000USDDisclosure
    Q4 2025Quarterly · 2025-04-30GeographyIE29,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-04-30GeographyInternational4,379,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-04-30GeographyUnited States4,548,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-04-30SegmentAll Other Segments30,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-04-30SegmentCardiovascular3,335,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-04-30SegmentDiabetes Group728,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-04-30SegmentMedical Surgical2,211,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-04-30SegmentNeuroscience Group2,620,000,000USDLegacy provider
    FY 2025Yearly · 2025-04-25GeographyIE116,000,000USDDisclosure
    FY 2025Yearly · 2025-04-25GeographyInternational16,365,000,000USDDisclosure
    FY 2025Yearly · 2025-04-25GeographyUnited States17,171,000,000USDDisclosure
    FY 2025Yearly · 2025-04-25SegmentCardiovascular12,481,000,000USDDisclosure
    FY 2025Yearly · 2025-04-25SegmentDiabetes Group2,755,000,000USDDisclosure
    FY 2025Yearly · 2025-04-25SegmentMedical Surgical8,407,000,000USDDisclosure
    FY 2025Yearly · 2025-04-25SegmentNeuroscience Group9,846,000,000USDDisclosure
    FY 2025Yearly · 2025-04-25SegmentOther Operating Segment Misc137,000,000USDDisclosure
    Q2 2025Quarterly · 2024-10-31GeographyIE29,000,000USDDisclosure
    Q2 2025Quarterly · 2024-10-31GeographyInternational4,099,000,000USDDisclosure
    Q2 2025Quarterly · 2024-10-31GeographyUnited States4,304,000,000USDDisclosure
    Q2 2025Quarterly · 2024-10-31SegmentAll Other Segments37,000,000USDDisclosure
    Q2 2025Quarterly · 2024-10-31SegmentCardiovascular3,102,000,000USDDisclosure
    Q2 2025Quarterly · 2024-10-31SegmentDiabetes Group686,000,000USDDisclosure
    Q2 2025Quarterly · 2024-10-31SegmentMedical Surgical2,128,000,000USDDisclosure
    Q2 2025Quarterly · 2024-10-31SegmentNeuroscience Group2,451,000,000USDDisclosure
    Q1 2025Quarterly · 2024-07-31GeographyIE30,000,000USDDisclosure
    Q1 2025Quarterly · 2024-07-31GeographyInternational3,832,000,000USDDisclosure
    Q1 2025Quarterly · 2024-07-31GeographyOther23,000,000USDDisclosure
    Q1 2025Quarterly · 2024-07-31GeographyUnited States4,082,000,000USDDisclosure
    Q1 2025Quarterly · 2024-07-31SegmentAll Other Segments38,000,000USDDisclosure
    Q1 2025Quarterly · 2024-07-31SegmentCardiovascular3,007,000,000USDDisclosure
    Q1 2025Quarterly · 2024-07-31SegmentDiabetes Group647,000,000USDDisclosure
    Q1 2025Quarterly · 2024-07-31SegmentMedical Surgical1,996,000,000USDDisclosure
    Q1 2025Quarterly · 2024-07-31SegmentNeuroscience Group2,317,000,000USDDisclosure
    FY 2024Yearly · 2024-04-30SegmentAll Other Segments221,000,000USDDisclosure
    FY 2024Yearly · 2024-04-30SegmentCardiovascular11,831,000,000USDDisclosure
    FY 2024Yearly · 2024-04-30SegmentDiabetes Group2,488,000,000USDDisclosure
    FY 2024Yearly · 2024-04-30SegmentMedical Surgical8,417,000,000USDDisclosure
    FY 2024Yearly · 2024-04-30SegmentNeuroscience Group9,406,000,000USDDisclosure
    FY 2024Yearly · 2024-04-30SegmentOther221,000,000USDDisclosure
    Q4 2024Quarterly · 2024-04-30GeographyIE28,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-04-30GeographyJapan Australia New Zealand Korea Canadaand Western Europe2,675,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-04-30GeographyMiddle East Africa Latin America Eastern Europeand Asia Excluding Japanand Korea1,573,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-04-30GeographyUnited States4,343,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-04-30SegmentAll Other Segments57,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-04-30SegmentCardiovascular3,129,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-04-30SegmentDiabetes Group660,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-04-30SegmentMedical Surgical2,197,000,000USDLegacy provider
    Q4 2024Quarterly · 2024-04-30SegmentNeuroscience Group2,544,000,000USDLegacy provider
    FY 2024Yearly · 2024-04-26GeographyIE113,000,000USDDisclosure
    FY 2024Yearly · 2024-04-26GeographyInternational15,802,000,000USDDisclosure
    FY 2024Yearly · 2024-04-26GeographyUnited States16,562,000,000USDDisclosure
    Q3 2024Quarterly · 2024-01-31GeographyIE27,000,000USD0001613103-24-000011
    Q3 2024Quarterly · 2024-01-31GeographyJapan Australia New Zealand Korea Canadaand Western Europe2,473,000,000USD0001613103-24-000011
    Q3 2024Quarterly · 2024-01-31GeographyMiddle East Africa Latin America Eastern Europeand Asia Excluding Japanand Korea1,495,000,000USD0001613103-24-000011
    Q3 2024Quarterly · 2024-01-31GeographyUnited States4,120,000,000USD0001613103-24-000011
    Q3 2024Quarterly · 2024-01-31SegmentAll Other Segments53,000,000USDDisclosure
    Q3 2024Quarterly · 2024-01-31SegmentCardiovascular2,929,000,000USDDisclosure
    Q3 2024Quarterly · 2024-01-31SegmentDiabetes Group640,000,000USDDisclosure
    Q3 2024Quarterly · 2024-01-31SegmentMedical Surgical2,112,000,000USDDisclosure
    Q3 2024Quarterly · 2024-01-31SegmentNeuroscience Group2,355,000,000USDDisclosure
    FY 2023Yearly · 2023-04-30GeographyIE98,000,000USD0001613103-24-000072
    FY 2023Yearly · 2023-04-30GeographyJapan Australia New Zealand Korea Canadaand Western Europe9,408,000,000USD0001613103-24-000072
    FY 2023Yearly · 2023-04-30GeographyMiddle East Africa Latin America Eastern Europeand Asia Excluding Japanand Korea5,446,000,000USD0001613103-24-000072
    FY 2023Yearly · 2023-04-30GeographyUnited States16,373,000,000USD0001613103-24-000072
    FY 2023Yearly · 2023-04-30SegmentAll Other Segments495,000,000USD0001613103-24-000072
    FY 2023Yearly · 2023-04-30SegmentCardiovascular11,522,000,000USD0001613103-24-000072
    FY 2023Yearly · 2023-04-30SegmentDiabetes Group2,262,000,000USD0001613103-24-000072
    FY 2023Yearly · 2023-04-30SegmentMedical Surgical7,989,000,000USD0001613103-24-000072

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.